Kiwamu Okita – författare

Cellular therapy with liver stem cells and their progeny, including bone marrow cells, is a promising new approach that will contribute significantly to the treatment of liver diseases. The existence of the liver stem cell had long been debated, but it is now generally accepted that the liver contains cells with stem-like properties and that these cells can be activated to proliferate and differentiate into mature hepatocytes under certain conditions. There is also a substantial body of evidence to suggest that oval cells are involved in liver regeneration as they differentiate into hepatocytes and biliary cells. This book is a collection of work on stem cell and liver regeneration, initially delivered at the 14th Yamaguchi (Japan) Symposium on Liver Disease. Its nine chapters present the most recent data about basic and clinical research in hepatology in Japan and other countries, providing a valuable resource for researchers and practitioners alike.

More than 2 million people in Japan have chronic hepatitis C and many of them will lose their lives to liver cirrhosis or complications of hepatocellular carcinoma. Hepatitis C virus-related diseases are a serious concern both in developing countries and in Japan and the United States, where the number of patients is also in the millions. Therapeutic modalities recently developed in Japan, including interferon therapy and nutritional supportive therapy, are gaining worldwide acceptance. At this critical juncture, HCV and Related Liver Diseases presents new information on etiology, pathology, diagnosis, and therapy. Viral hepatitis was the theme of the Yamaguchi Symposium on Liver Disease, meeting in December 1998 and attended by leading hepatologists and virologists. Collected in this volume are the papers from the symposium, providing a valuable resource for hepatologists, gastroenterologists, and others working to understand and treat viral hepatitis.

More than 2 million people in Japan have chronic hepatitis C and many of them will lose their lives to liver cirrhosis or complications of hepatocellular carcinoma. Hepatitis C virus-related diseases are a serious concern both in developing countries and in Japan and the United States, where the number of patients is also in the millions. Therapeutic modalities recently developed in Japan, including interferon therapy and nutritional supportive therapy, are gaining worldwide acceptance. At this critical juncture, HCV and Related Liver Diseases presents new information on etiology, pathology, diagnosis, and therapy. Viral hepatitis was the theme of the Yamaguchi Symposium on Liver Disease, meeting in December 1998 and attended by leading hepatologists and virologists. Collected in this volume are the papers from the symposium, providing a valuable resource for hepatologists, gastroenterologists, and others working to understand and treat viral hepatitis.

More than 2 million people in Japan have chronic hepatitis C and many of them will lose their lives to liver cirrhosis or complications of hepatocellular carcinoma. Hepatitis C virus-related diseases are a serious concern both in developing countries and in Japan and the United States, where the number of patients is also in the millions. Therapeutic modalities recently developed in Japan, including interferon therapy and nutritional supportive therapy, are gaining worldwide acceptance. At this critical juncture, HCV and Related Liver Diseases presents new information on etiology, pathology, diagnosis, and therapy. Viral hepatitis was the theme of the Yamaguchi Symposium on Liver Disease, meeting in December 1998 and attended by leading hepatologists and virologists. Collected in this volume are the papers from the symposium, providing a valuable resource for hepatologists, gastroenterologists, and others working to understand and treat viral hepatitis.